title: Pharmacogenetics of osteoporosis.
abstract: The challenge of personalized medicine is to move away from the traditional 'one-size-fits-all' pharmacology to genotype-based individualized therapies. As an individual's response to drugs is under the control of genes, personal genetic profiles could help clinicians to predict individual drug response and prescribe the right drug and dose, thereby optimising efficacy and avoiding risk of adverse effects. Currently, the concrete application of pharmacogenetics into clinical practice is limited to a few drugs, and the genetic prediction of drug response is far from clear for many of thve principal complex disorders. This is even more evident in the field of osteoporosis and metabolic bone disorders, for which few pharmacogenetic studies have been conducted, and no conclusive results are available. In this chapter, we review recent research on pharmacogenetics of osteoporosis, evaluate criticisms, and offer possible suggestions for improvements in this field and for possible future applications into clinical practice.
authors.affiliation: Metabolic Bone Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. Electronic address: f.marini@dmi.unifi.it.
authors.forename: Francesca
authors.initials: F
authors.lastname: Marini
authors.affiliation: Metabolic Bone Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy. Electronic address: marialuisa.brandi@unifi.it.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Brandi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000069448:Denosumab; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000235:genetics*; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D000069448:Denosumab
keywords: anti-fracturative drugs; drug response; gene polymorphism; osteoporosis; pharmacogenetics